TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03430544
Drug: Cariprazine Oral Capsule [Vraylar]
Normalized name: cariprazine Oral Capsule [Vraylar]
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cariprazine Groups (1.5 or 3mg/d): Cariprazine (VRAYLAR) capsules will be administered orally, once per day. Subjects in the 1.5mg group will receive 1 VRAYLAR capsule containing 1.5 mg cariprazine each day that study drug is administered. Subjects in the 3 mg group will be gradually titrated up to full dose: they will receive 1 VRAYLAR capsule containing 1.5mg cariprazine on the first and second days that study drug is administered and will receive 1 VRAYLAR capsule containing 3mg cariprazine each day for the rest of the medication period. The study medication period begins during the inpatient/induction phase and ends on the last day of outpatient treatment week 8 (approx. 10 weeks total). All VRAYLAR capsules will be over-encapsulated by the University of Pennsylvania Investigational Drug Services (IDS).
Study: NCT00416598
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00416598
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00416598
Drug: Daunorubicin Hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00416598
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00416598
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03102489
Drug: BP101
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nasal spray
Study: NCT00347698
Drug: intravitreal injection of bevacizumab
Normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03439358
Drug: Magnesium Sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bolus infusion: 100mL normal saline with 4g MgSO4 over 30 minutes Maintenance infusion: 25mL normal saline per hour with 1g MgSO4
Study: NCT00004585
Drug: Abacavir sulfate, Lamivudine and Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004585
Drug: Lamivudine/Zidovudine
Normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004585
Drug: Abacavir sulfate
Normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00004585
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02308332
Drug: Eviplera
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: switch from Atripla to emtricitabine/rilpivirine/tenofovir (Eviplera)
Study: NCT00291655
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg oral tablets,1000 - 3000 mg/day, twice a day (BID), duration of the study
Study: NCT02356705
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: midazolam 0.2 mg/kg given intranasally
Study: NCT02356705
Drug: xylocaine
Normalized name: Xylocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intransal xylocaine given in conjunction with intranasal midazolam
Study: NCT02693197
Drug: T-817MA
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of 448 mg
Study: NCT00044746
Drug: Piperacillin/Tazobactam
Normalized name: PIPERACILLIN/TAZOBACTAM
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03481790
Drug: Lactoferrin
Normalized name: Lactoferrin
DrugBank: Lactoferrin (DB16555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Pravotin sachets, Hygint, Egypt): 100 mg in 1/4 glass of water before meals twice a day for 4 weeks.
Study: NCT00836173
Drug: RICE
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RICE treatment: Rituximab by intravenous infusion over 6-8 hours on day 1, Eptoposide by intravenous infusion over 2 hours on day 3-5, a 1-hour infusion of Carboplatin on day 4 and a 24-hour infusion of Ifosfamide on day 4, each cycle is 14 days (2 weeks). Patients will receive 3 cycles of RICE treatment.
Study: NCT00836173
Drug: GaRD Treatment
Normalized name: S.Gard
DrugBank: Garden snail mucin (DB14244)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After RICE treatment, patients will have gallium nitrate IV through a vein continuously over a 7 day period. Patients will also receive rituximab by intravenous infusion over a 3-6 hour period on day 1 of each cycle. Dexamethasone will be given as pills to be taken for 4 days in a row on the first 4 days of each cycle. The length of each cycle is 21 days (3 weeks). All patients will have 2 cycles of GaRD.
Study: NCT01270828
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, 82.5 to 660mg, once per day. Duration: 19 weeks
Study: NCT02453061
Drug: Triheptanoin oil
DrugBank: Triheptanoin (DB11677)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triheptanoin oil orally administered at 1g/kg/day
Study: NCT01026909
Drug: Aristospan 20mg
Normalized name: Aristospan 20mg/ml Suspension for Injection
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone hexacetonide injectable suspension, USP, 20mg/mL Parenteral. One single dose.
Study: NCT04692844
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive Propranolol in the course of their routine treatment. Results will be used to explore biological phenomena or disease processes.
Study: NCT04692844
Drug: Primidone
Normalized name: Primidone
DrugBank: Primidone (DB00794)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive Primidone in the course of their routine treatment. Results will be used to explore biological phenomena or disease processes.
Study: NCT02357888
Drug: V0018
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oromucosal - Single dose
Study: NCT01475461
Drug: PF-04937319 - 3mg
Normalized name: PF-04937319
DrugBank: PF-04937319 (DB15009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04937319 3mg administered as tablets once-daily for 84-days
Study: NCT01475461
Drug: PF-04937319 - 20mg
Normalized name: cytarabine
DrugBank: PF-04937319 (DB15009)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PF-04937319 20mg administered as tablets once-daily for 84-days
Study: NCT01475461
Drug: PF-04937319 - 50mg
Normalized name: oxaliplatin
DrugBank: PF-04937319 (DB15009)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PF-04937319 50mg administered as tablets once-daily for 84-days
Study: NCT01475461
Drug: PF-04937319 - 100mg
Normalized name: cisplatin
DrugBank: PF-04937319 (DB15009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PF-04937319 100mg administered as tablets once-daily for 84-days
Study: NCT01475461
Drug: Sitagliptin - 100mg
Normalized name: SITagliptin 100 MG
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin 100mg administered as tablets once-daily for 84-days
Study: NCT02643719
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preventive medication prescriptions given to the patient along with written instructions and information about side effects:~Topiramate 25mg tabs (with a plan to increase to 100mg)
Study: NCT02643719
Drug: Abortive Medication (Naproxen and Sumatriptan)
Normalized name: sumatriptan and naproxen
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will receive abortive medication for acute treatment of their migraine. Preferred medications are Naproxen (500mg) and Sumatriptan (100mg)
Study: NCT04197076
Drug: anti-PD-1 or anti-PD-L1
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: immunotherapy anti-PD-1 or anti-PD-L1
Study: NCT00508495
Drug: Paracetamol (acetaminophen)
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Four 100 mL, 15 min IV infusions at six hour intervals
Study: NCT02095990
Drug: Hydroquinone
Normalized name: Hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00077636
Drug: Copegus
Normalized name: Copegus
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg po bid for 16 weeks
Study: NCT00077636
Drug: Copegus
Normalized name: Copegus
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg po bid for 24 weeks
Study: NCT00077636
Drug: peginterferon alfa-2a [Pegasys]
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180 micrograms sc weekly for 16 weeks
Study: NCT00077636
Drug: peginterferon alfa-2a [Pegasys]
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180 micrograms sc weekly for 24 weeks
Study: NCT00508495
Drug: 0.9% sodium chloride solution
Normalized name: Precedex 80mcg/20mL in 0.9% Sodium Chloride Solution for Injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Four 100 mL, 15 min IV infusions at six hour intervals
Study: NCT03029247
Drug: Daprodustat
Normalized name: daprodustat
DrugBank: Daprodustat (DB11682)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Daprodustat will be available as oral tablets at unit dose strength of 1, 2, 4, 6, 8 and 10 mg.
Study: NCT03029247
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa will be administered according to local labelling and clinical practice guidelines to keep Hgb in the target range (10.0-11.0 g/dL)
Study: NCT01045122
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For propofol, the current study will employ the Marsh parameters, with an initial effect site target concentration of 1.0 mcg/ml, a level likely to produce only mild sedation. Though our patient population is expected to be predominantly obese, a previous pharmacokinetic study has validated that constant infusions utilizing the dosing scheme of mcg-1•kg-1•min will yield similar effect site concentrations.25 The effect site target will be increased in increments approximately every five minutes until the pharmacodynamic targets defined in the study are attained.
Study: NCT01045122
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For dexmedetomidine, an intravenous loading dose of 0.5 mcg/kg will be infused over 10 minutes and followed by an infusion starting at 0.5 mcg/kg/hr. This infusion will be titrated up to a maximum of 1.2 mcg/kg/hr.
Study: NCT01694810
Drug: Vehicle Topical Gel
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Topical Gel applied once daily
Study: NCT00807521
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single high dose bolus of dexamethasone before surgery
Study: NCT02264119
Drug: Lefradafiban tablet
Normalized name: Lefradafiban
DrugBank: Lefradafiban (DB04863)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02264119
Drug: Pantoprazole tablet
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02678767
Drug: Ferumoxytol
Normalized name: Ferumoxytol
DrugBank: Ferumoxytol (DB06215)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
Study: NCT00082537
Drug: caspofungin acetate
Normalized name: Caspofungin Acetate
DrugBank: Caspofungin (DB00520)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duration of Treatment: 28-90 days
Study: NCT03845270
Drug: pertuzumab + trastuzumab + docetaxel
Normalized name: hyaluronidase / pertuzumab / trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cycle 1 : D1 : pertuzumab 840 mg, D2 : trastuzumab 8 mg/kg + docetaxel 75 mg/m² Subsequent cycle : D1 : pertuzumab 420 mg + trastuzumab 6 mg/kg + docetaxel 75 mg/m²
Study: NCT01317875
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose of ruxolitinib for cohort 1 in dose escalation phase - 5mg twice a day (BID)~Doses will be increased a total of approximately 5mg for successive dosing cohorts based on baseline platelet count
Study: NCT01306721
Drug: fexofenadine HCL (M016455)
Normalized name: Fexofenadine Hydrochloride
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT01306721
Drug: pseudoephedrine
Normalized name: Pseudoephedrine
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet~Route of administration: oral
Study: NCT01306721
Drug: fexofenadine HCL matching placebo
Normalized name: Fexofenadine Hydrochloride
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet~Route of administration: oral
Study: NCT01306721
Drug: pseudoephedrine matching placebo
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet~Route of administration: oral
Study: NCT00027638
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01076790
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine infusion 1 mcg/kg in 10 minutes; thereafter 0.7 mcg/kg/h until 30 minutes has elapsed from skin incision.
Study: NCT01076790
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline infusion 1 mcg/kg in 10 minutes; thereafter 0.7 mcg/kg/h until 30 minutes has elapsed from skin incision.
Study: NCT02670538
Drug: Cariprazine
Normalized name: Cariprazine
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cariprazine capsule one per day orally.
Study: NCT04205357
Drug: Sulfasalazine
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfasalazine combined with stereotactic radiosurgery
Study: NCT00404534
Drug: Amoxicillin, Clarythromycin, Omeprazole for ten days
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 1000 mg BID, clarythromycin 500 mg BID for ten days in the experimental group and placebo of Amoxicillin 1000 mg BID and placebo of clarythromycin 500 mg BID in the placebo comparator. Both groups receive omeprazole 20 mg bid for 10 days.
Study: NCT02960763
Drug: Aripiprazole Augmentation
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Augment current antidepressant treatment with aripiprazole (tablets). Start at 2 mg daily; increase every two weeks (i.e., to 5, 7, 10 mg) to a maximum of 15 mg daily based on symptom severity and side effects.
Study: NCT02960763
Drug: Bupropion Augmentation
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Augment current antidepressant treatment with bupropion once-daily extended release, starting at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
Study: NCT02960763
Drug: Switch to bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taper from current antidepressant therapy. Start bupropion once-daily extended release at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
Study: NCT02960763
Drug: Lithium Augmentation
DrugBank: Lithium citrate (DB14507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.
Study: NCT01632189
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Varenicline will be administered as prescribed: 0.5 mg for the first 3 days then 1 mg for the next 7 days and 2 mg after that. A quit date will be chosen at 11 days after starting Varenicline. Varenicline will be given for 3 months.
Study: NCT03603639
Drug: E2730
Normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive E2730 capsule, orally.
Study: NCT02960763
Drug: Switch to nortriptyline
DrugBank: Nortriptyline (DB00540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml
Study: NCT01896180
Drug: Latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost 0.005% Ophthalmic Solution
Study: NCT02934204
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00607672
Drug: Ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril 2.5mg day 1 and 2 and then 5mg/d thereafter
Study: NCT00607672
Drug: Candesartan
Normalized name: Candesartan
DrugBank: Candesartan (DB13919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 16mg/d
Study: NCT02002962
Drug: Botulinum Toxin Type A injection
Normalized name: botulinum toxin type A Injection
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Study: NCT01216072
Drug: Fingolimod
Normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 0.5 mg/day oral capsule
Study: NCT01216072
Drug: Standard MS DMTs
Normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00218361
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00720408
Drug: Prograf
Normalized name: Prograf
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT00720408
Drug: MMF
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00532168
Drug: tenofovir + emtricitabine + efavirenz
Normalized name: efavirenz / emtricitabine / tenofovir disoproxil
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tenofovir + emtricitabine + efavirenz, approved dose, oral route, QD
Study: NCT00532168
Drug: tenofovir + emtricitabine + lopinavir-ritonavir
Normalized name: lopinavir / ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: tenofovir + emtricitabine (QD) + lopinavir-ritonavir (BID), oral route, approved dose
Study: NCT00532168
Drug: tenofovir + emtricitabine + atazanavir-ritonavir
Normalized name: emtricitabine / tenofovir disoproxil
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: tenofovir + emtricitabine + atazanavir + ritonavir (100 mg), oral route, approved dose, QD
Study: NCT02057575
Drug: Netarsudil (AR-13324) Ophthalmic Solution 0.02%
DrugBank: Netarsudil (DB13931)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 drop in the evening (PM), once daily (QD), both eyes (OU)
Study: NCT02057575
Drug: Latanoprost Ophthalmic Solution 0.005%
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 drop in the evening (PM), once daily (QD), both eyes (OU)
Study: NCT03051490
Drug: Liprotamase
Normalized name: Liprotamase
DrugBank: Liprotamase protease (DB16584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
Study: NCT03051490
Drug: porcine PERT
Normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral, enterically-coated, pig-derived, pancreatic enzyme replacement
Study: NCT00224029
Drug: Oxybutynin transdermal system
Normalized name: oxyBUTYnin Transdermal System
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3.9 mg/day, 7.8 mg/day, 9.1 mg/day or 11.7 mg/day transdermal per titration
Study: NCT02315768
Drug: ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01512797
Drug: Sitagliptin phosphate
Normalized name: Sitagliptin Phosphate
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100 mg/day orally
Study: NCT00776022
Drug: Cetirizine Hydrochloride 10 mg tablet
Normalized name: cetirizine
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bioequivalence Cetirizine Hydrochloride 10 mg tablet fed conditions
Study: NCT00786643
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU bolus was administered at 400mg/m\^2 on day 1 and day 2 of each cycle. 5-FU at 600 mg/m\^2 infusion was administered over 22 hours on day 1 and day 2 of each cycle.
Study: NCT02874664
Drug: Rovalpituzumab Tesirine
Normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC)
Study: NCT00786643
Drug: Gamma-Interferon-1b (IFN-γ)
Normalized name: Interferon Gamma-1B
DrugBank: Interferon gamma-1b (DB00033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma-Interferon 150 mcg/m\^2 was administered by subcutaneous injection on day 1 of each cycle immediately before treatment with 5-FU and LV, and on day 3 of each cycle immediately after treatment with 5-FU and LV.
Study: NCT00786643
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 5mg/kg was only added to the treatment regimen of patients in stratum 1 who demonstrated stable disease on imaging repeated prior to the 5th cycle of treatment. Bavacizumab was administered on day 4 of each cycle.